Article Text

Download PDFPDF
BASHH feedback from the 2023 IUSTI-Europe conference in Malta
  1. Daniel Richardson1,2,
  2. Michael Butler3,
  3. Oliver Bull Olozabal4,
  4. Nadi Gupta5,
  5. Fahad Naser4,
  6. Binta Sultan6,
  7. Rachel J Caswell7
  1. 1 Sexual Health and HIV, University Hospitals Sussex NHS Foundation Trust, Brighton, UK
  2. 2 Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK
  3. 3 Jefferiss Wing, Imperial College Healthcare NHS Trust, London, UK
  4. 4 Sexual Health and HIV, London North West University Healthcare NHS Trust, Harrow, London, UK
  5. 5 Sexual Health and HIV, Rotherham NHS Foundation Trust, Rotherham, UK
  6. 6 Central and North West London NHS Foundation Trust, London, UK
  7. 7 Sexual Health and HIV Medicine, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
  1. Correspondence to Professor Daniel Richardson, Sexual Health & HIV, University Hospitals Sussex NHS Foundation Trust, Brighton, UK; daniel.richardson7{at}nhs.net

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

There is a growing relationship between BASHH and IUSTI.1 In 2023, several BASHH scholars were invited to give feedback on the IUSTI conference in Malta.

Asymptomatic STI screening: Chris Kenyon, (Belgium)

Despite good evidence for HIV and syphilis screening in asymptomatic patients, evidence is lacking for other STIs, for example, Neisseria gonorrhoeae and Chlamydia trachomatis. Kenyon et al 2 highlighted the potential harms of widespread screening for asymptomatic STIs, particularly in HIV-pre-exposure prophylaxis (HIV-PrEP) cohorts, namely increased antimicrobial consumption and antimicrobial resistance (AMR). In Belgium, clinics have reduced asymptomatic STI screening in men who have sex with men using HIV-PrEP: what we need now are patient perspectives and involvement if we are to reduce screening in an attempt to curtail AMR.

STIs in teenagers & adolescents: Errol Fields, (USA)

Fields et al 3 presented interventions developed in Baltimore, USA, to …

View Full Text

Footnotes

  • Handling editor Anna Maria Geretti

  • Contributors DR and RJC conceived this BASHH column, DR drafted the section on asymptomatic STI testing, MB drafted the section on STIs in teenagers and adolescents, OBO drafted the section on doxycycline for STI prophylaxis, NG drafted the section on non-fatal strangulation, FN drafted the section on genital dermatoses, BS drafted the section on hepatitis B. DR, MB, OBO, NG, FN, BS and RJC all contributed to the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests DR, MB, OBO, NG, FN and BS received BASHH scholarships to attend the IUSTI conference in Malta.

  • Provenance and peer review Not commissioned; internally peer reviewed.